Welcome to Sun-shine chemical
+86-27-65522453 sales@sun-shinechem.com

Emricasan

Catalog No.: 16071024
Cas No.: 254750-02-2
Purity : 98%

Emricasan (IDN-6556, PF-03491390) is a potent irreversible pan-caspase inhibitor with the ability to rapidly reduce elevated levels of serum ALT, AST and caspase mediated cleavage of cytokeratin-18 in HCV infected patients. 1,2,3 To date, emricasan has been studied in more than 550 individuals and has exhibited a safety profile similar to placebo.

Emricasan is currently in three Phase 2 clinical trials, including two trials in patients with liver cirrhosis. Here we report the effect of emricasan in healthy volunteers on measures of serum caspase activity and apoptosis. These results are compared with the effect of emricasan in subjects with varying degrees of hepatic impairment, as well as the effect of emricasan in subjects with severe renal impairment.

For research use only. We do not sell to patients.

Chemical Information

NameEmricasan
Iupac Chemical Name(S)-3-((S)-2-(2-((2-(tert-butyl)phenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 
SynonymsIDN-6556;IDN6556;PF 03491390;PF-03491390;Emricasan;PF03491390
Molecular FormulaC26H27F4N3O7 
Molecular Weight569.51 
SmileC(C)(C)(C)C1=C(C=CC=C1)NC(C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(COC1=C(C(=CC(=C1F)F)F)F)=O)C)=O
InChiKeySCVHJVCATBPIHN-SJCJKPOMSA-N
InChiInChI=1S/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1
CAS Number254750-02-2
Related CAS

Ordering Information

PackagingPriceAvailabilityPurityShipping Time
BulkEnquiryEnquiryEnquiry
Request Bulk Quote Download MSDS Tel : +86-27-65522453   Email : sales@sun-shinechem.com
FormulationOff-white powder 
Purity98%
Storage-20 ºC for 3 years 
SolubilitySoluble in DMSO 
Handling
Shipping ConditionShipped under ambient temperature 
HS Code
Coming soon.
Targets
Mechanism
Cell study
Animal study
Clinical study

1.       Frenette CT1, Morelli G2, Shiffman ML3, etc.Emricasan Improves Liver Function in PatientsWith Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo. Clin Gastroenterol Hepatol. 2019 Mar;17(4):774-783.e4. doi: 10.1016/j.cgh.2018.06.012. Epub 2018 Jun 18.

2.       Khurana S1, Khara HS1. Is Emricasan (IDN-6556), an oral pan-caspase inhibitor, ready for controlled trials? Hepatology. 2019 May 2. doi: 10.1002/hep.30683.


Chemical Structure

16071024 - Emricasan | CAS 254750-02-2

Quick inquiry

Change